Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Wierda W, Brown J, Abramson J, Awan F, Bilgrami S, Bociek G, Brander D, Cortese M, Cripe L, Davis R, Eradat H, Fakhri B, Fletcher C, Gaballa S, Hamid M, Hill B, Kaesberg P, Kahl B, Kamdar M, Kipps T, Ma S, Mosse C, Nakhoda S, Parikh S, Schorr A, Schuster S, Seshadri M, Siddiqi T, Stephens D, Thompson M, Ujjani C, Valdez R, Wagner-Johnston N, Woyach J, Sundar H, Dwyer M. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22: 175-204. PMID: 38626800, DOI: 10.6004/jnccn.2024.0018.Peer-Reviewed Original ResearchConceptsSmall lymphocytic lymphomaChronic lymphocytic leukemiaPredictor of improved survivalUndetectable minimal residual diseaseImmunoglobulin heavy chain variable region mutational statusMinimal residual diseaseManagement of patientsSelection of treatmentRelapsed/refractory CLL/SLLLymphocytic lymphomaResidual diseaseCombination regimensTP53 mutationsMutation statusPerformance statusLymphocytic leukemiaNCCN GuidelinesPatient agePrognostic implicationsToxicity profileDisease stageComorbid conditionsPatientsCLL/SLLCytogenetic variability